|Table of Contents|

Comparison of efficacy between surgical treatment and postoperative adjuvant for intrahepatic cholangiocinoma patients:A propensity score matching study based on the SEER database

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 03
Page:
495-499
Research Field:
Publishing date:

Info

Title:
Comparison of efficacy between surgical treatment and postoperative adjuvant for intrahepatic cholangiocinoma patients:A propensity score matching study based on the SEER database
Author(s):
PAN Xiaotao1; NAN Hong2; CAO Qiuxiang3
1.Department of General Surgery,Shaanxi Provincial Cancer Hospital,Shaanxi Xi'an 710061,China;2.Department of Surgery,521 Hospital of Ordnance Industry,Shaanxi Xi'an 710061,China;3.Department of Surgery,Caijiapo Hospital of Baoji City,Shaanxi Baoji 722405,China.
Keywords:
intrahepatic cholangiocarcinoma; postoperative radiotherapy; propensity score matching; overall survival; liver cancer specific survival
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2022.03.024
Abstract:
Objective:To compare the survival of patients with intrahepatic cholangiocarcinoma(ICC) after surgical treatment with postoperative radiotherapy,to explore the feasibility of postoperative adjuvant radiotherapy,and to provide a basis for the clinical treatment of ICC.Methods:The clinical data of patients diagnosed as ICC in The Surveillance,Epidemiology and End Results(SEER) database from 2004 to 2015 were extracted.Patients were divided into surgery group and post-operative radiotherapy group.Using Kaplan-Meier method to compare the overall survival(OS) and liver cancer specific survival(LCSS) difference between the two groups.After 1∶1 propensity score matching(PSM),the difference between OS and LCSS was compared again.Then a subgroup analysis was performed to compare the efficacy of the surgery group and the postoperative radiotherapy group.Finally,data from our hospital were collected to verify the database results.Results:A total of 470 patients were included in the study,including 410 patients in the surgery group and 60 patients in the postoperative radiotherapy group.There was no significant difference between the medium OS(19.00 months vs 26.00 months,P=0.268) and the medium LCSS(19.00 months vs 26.00 months,P=0.591) between the surgery group and the postoperative radiotherapy group before PSM.The medium OS(25.50 months vs 26.00 months,P=0.531) and the medium LCSS(27.00 months vs 26.00 months,P=0.302) were also not significantly different after PSM.In the subgroup analysis,postoperative radiotherapy was not a protective factor for the overall survival of ICC patients.The data results of our hospital were consistent with the database results.Conclusion:Compared with surgical treatment,adjuvant radiotherapy for ICC patients does not prolong survival.

References:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2] SAHA SK,ZHU AX,FUCHS CS,et al.Forty-year trends in cholangiocarcinoma incidence in the US:Intrahepatic disease on the rise［J］.Oncologist,2016,21(5):594-599.
[3] BENSON AB,D'ANGELICA MI,ABBOTT DE,et al.Guidelines insights:Hepatobiliary cancers,version 2.2019［J］.J Natl Compr Canc Netw,2019,17(4):302-310.
[4] DE JONG MC,NATHAN H,SOTIROPOULOS GC,et al.Intrahepatic cholangiocarcinoma:an international multi-institutional analysis of prognostic factors and lymph node assessment［J］.J Clin Oncol,2011,29(23):3140-3145.
[5] MACHAIRAS N,LANG H,JAYANT K,et al.Intrahepatic cholangiocarcinoma:Limitations for resectability,current surgical concepts and future perspectives［J］.Eur J Surg Oncol,2020,46(5):740-746.
[6] WANG L,DENG M,KE Q,et al.Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma:A multicenter retrospective study［J］.Cancer Med,2020,9(8):2674-2685.
[7] KE Q,LIN N,DENG M,et al.The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection:A systematic review and meta-analysis［J］.PLoS One,2020,15(2):e229292.
[8] SCHWEITZER N,WEBER T,KIRSTEIN M,et al.The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma:a matched pair analysis［J］.J Cancer Res Clin Oncol,2017,143(7):1347-1355.
[9] MA KW,CHEUNG TT,LEUNG B,et al.Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma:A meta-analysis［J］.Medicine(Baltimore),2019,98(5):e14013.
[10] REAMES BN,BAGANTE F,EJAZ A,et al.Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma:a multi-institutional analysis［J］.HPB(Oxford),2017,19(10):901-909.
[11] WANG ML,KE ZY,YIN S,et al.The effect of adjuvant chemotherapy in resectable cholangiocarcinoma:A meta-analysis and systematic review［J］.Hepatobiliary Pancreat Dis Int,2019,18(2):110-116.
[12] LI T,QIN L X,ZHOU J,et al.Staging,prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection［J］.Liver Int,2014,34(6):953-960.
[13] WU ZF,ZHANG HB,YANG N,et al.Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors:results of a large monocentric series［J］.Eur J Surg Oncol,2012,38(7):602-610.
[14] ZHENG X,CHEN B,WU JX,et al.Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels［J］.Cancer Manag Res,2018,10:3973-3981.
[15] HAMMAD AY,BERGER NG,EASTWOOD D,et al.Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? The impact of surgical margins and lymph node status on survival［J］.Ann Surg Oncol,2016,23(Suppl 5):912-920.

Memo

Memo:
-
Last Update: 2021-12-31